Stock LWACU LOCT WALK
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

LOCT WALK Stock Nasdaq

Equities

LWACU

US54015L3015

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 1.36M
Net income 2024 * -34M Net income 2025 * -37M EV / Sales 2024 * -
Net cash position 2024 * 18M Net cash position 2025 * 51M EV / Sales 2025 * -
P/E ratio 2024 *
-0.05 x
P/E ratio 2025 *
-0.13 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data

Chart LOCT WALK

Dynamic Chart

Latest news about LOCT WALK

Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Advance Monday Afternoon MT
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives MT
EFFECTOR Therapeutics, Inc Appoints Craig R. Jalbert as CEO CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board CI
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Health Care Down on Retreat From Risk -- Health Care Roundup DJ
Top Midday Decliners MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer CI
Top Premarket Decliners MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
More news

Latest transcript on LOCT WALK

Logo LOCT WALK
EFFECTOR Therapeutics, Inc. - Special Call
More transcripts

Analyst Recommendations on LOCT WALK

HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target MT
Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30 MT
Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating MT
Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating MT
JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating MT
More recommendations

Press releases LOCT WALK

EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K PU
EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq AQ
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer AQ
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AQ
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
More press releases

Company Profile

Locust Walk Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company focuses to identify and acquire a business, focusing on the healthcare or healthcare related industries in the United States and Europe. The Company has no business operations and has no revenues.
Sector
-
Calendar
2024-08-05 - Q2 2024 Earnings Release (Projected)
More about the company
  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. LWACU Stock